Zoetis Inc. $ZTS Shares Sold by Fieldview Capital Management LLC

Fieldview Capital Management LLC reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 49.0% during the third quarter, Holdings Channel reports. The firm owned 10,039 shares of the company’s stock after selling 9,655 shares during the period. Fieldview Capital Management LLC’s holdings in Zoetis were worth $1,469,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ZTS. Vanguard Group Inc. grew its position in Zoetis by 1.0% in the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after buying an additional 419,777 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after buying an additional 95,294 shares in the last quarter. Norges Bank acquired a new stake in shares of Zoetis during the 2nd quarter valued at $809,491,000. Brown Advisory Inc. lifted its position in shares of Zoetis by 5.7% during the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after acquiring an additional 250,829 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after acquiring an additional 550,859 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on ZTS shares. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Stifel Nicolaus reduced their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. Barclays started coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price target for the company. HSBC set a $140.00 price objective on Zoetis in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research note on Monday, December 15th. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $122.29 on Tuesday. The company’s fifty day moving average is $125.99 and its two-hundred day moving average is $132.65. The company has a market cap of $51.62 billion, a P/E ratio of 20.31, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.00. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter last year, the firm posted $1.40 earnings per share. Zoetis’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.